当前位置: 首页 >> 检索结果
101. Vitamin D receptor gene polymorphisms and osteoarthritis: a meta-analysis.
作者: Hui-Min Li.;Yi Liu.;Ren-Jie Zhang.;Jing-Yu Ding.;Cai-Liang Shen.
来源: Rheumatology (Oxford). 2021年60卷2期538-548页
To investigate the association of vitamin D receptor (VDR) gene polymorphisms with OA susceptibility.
102. Systematic review and meta-analysis of epidemiological studies on the association of occupational exposure to free crystalline silica and systemic lupus erythematosus.
作者: Alberto Morotti.;Irena Sollaku.;Simona Catalani.;Franco Franceschini.;Ilaria Cavazzana.;Micaela Fredi.;Emma Sala.;Giuseppe De Palma.
来源: Rheumatology (Oxford). 2021年60卷1期81-91页
Some evidence suggests that exposure to free crystalline silica may contribute to the risk of developing SLE. A systematic search was carried out for all published epidemiological studies concerning this association. A meta-analysis was conducted on relevant studies.
103. The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis.
作者: José María Pego-Reigosa.;Lindsay Nicholson.;Nick Pooley.;Sue Langham.;Nina Embleton.;Zoe Marjenberg.;Volkan Barut.;Barnabas Desta.;Xia Wang.;Julia Langham.;Edward R Hammond.
来源: Rheumatology (Oxford). 2021年60卷1期60-72页
We conducted a systematic review and meta-analysis to determine the magnitude of infection risk in patients with SLE and evaluate the effect of general and SLE-related factors on infection risk.
104. Which disease activity outcome measure discriminates best in axial spondyloarthritis? A systematic literature review and meta-analysis.
作者: Augusta Ortolan.;Victoria Navarro-Compán.;Alexandre Sepriano.;Robert B M Landewé.;Désirée van der Heijde.;Sofia Ramiro.
来源: Rheumatology (Oxford). 2020年59卷12期3990-3992页 105. Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies.
作者: Désirée van der Heijde.;Robert B M Landewé.;Jürgen Wollenhaupt.;Sander Strengholt.;Ketti Terry.;Kenneth Kwok.;Lisy Wang.;Stanley Cohen.
来源: Rheumatology (Oxford). 2021年60卷4期1708-1716页
Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. We evaluated radiographic progression in tofacitinib-treated patients with RA for up to 3 years in two pooled long-term extension (LTE) studies (ORAL Sequel; A3921041) (primary analysis), and for up to 5 years using data integrated from one phase (P)2 (A3921068), two P3 (ORAL Start; ORAL Scan) and two LTE studies (exploratory analysis).
106. Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis.
作者: Sizheng Steven Zhao.;Selina Robertson.;Tzvi Reich.;Nicolas L Harrison.;Robert J Moots.;Nicola J Goodson.
来源: Rheumatology (Oxford). 2020年59卷Suppl4期iv47-iv57页
Comorbidities are common in people with axial spondyloarthritis (axSpA). In this systematic review and meta-analysis, we aimed to: (i) describe the prevalence of commonly reported comorbidities, (ii) compare comorbidities between axSpA and control populations, and (iii) examine the impact of comorbidity burden on axSpA outcomes.
107. Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis.
作者: Yantao Xu.;Yuting Li.;Mengyuan Dong.;Zi'ang Gao.;Xiang Chen.;Hong Liu.;Minxue Shen.
来源: Rheumatology (Oxford). 2020年59卷12期3657-3665页
We sought to systematically investigate the effectiveness of secukinumab in psoriatic arthritis (PsA) patients who previously received TNFs inhibitor (TNFi) treatment and those who were TNFi naïve.
108. Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus.
作者: Alvaro Gomez.;Fawz Hani Butrus.;Petter Johansson.;Emil Åkerström.;Sofia Soukka.;Sharzad Emamikia.;Yvonne Enman.;Susanne Pettersson.;Ioannis Parodis.
来源: Rheumatology (Oxford). 2021年60卷3期1260-1272页
Associations between BMI and health-related quality of life (HRQoL) in SLE have been implied, but data are scarce. We determined the impact of overweight and obesity on HRQoL in a large SLE population.
109. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials.
作者: Alemnew F Dagnew.;Debora Rausch.;Caroline Hervé.;Toufik Zahaf.;Myron J Levin.;Anne Schuind.; .
来源: Rheumatology (Oxford). 2021年60卷3期1226-1233页
In the ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials, the adjuvanted recombinant zoster vaccine (RZV) demonstrated ≥90% efficacy in preventing herpes zoster (HZ) in all age groups ≥50 years. Given the increased HZ risk associated with certain underlying autoimmune diseases or their treatment regimes, we conducted a post hoc analysis of RZV's efficacy against HZ and safety profile [specifically, the occurrence of serious adverse events (SAEs)] in ZOE-50/70 participants who reported pre-existing potential immune-mediated diseases (pIMDs) at enrolment and were not on immunosuppressive therapies.
110. Association of systemic lupus erythematosus with peripheral arterial disease: a meta-analysis of literature studies.
作者: Francesco Forte.;Alessio Buonaiuto.;Ilenia Calcaterra.;Gabriella Iannuzzo.;Pasquale Ambrosino.;Matteo Nicola Dario Di Minno.
来源: Rheumatology (Oxford). 2020年59卷11期3181-3192页
SLE patients have an increased cardiovascular morbidity and mortality. Contrasting data are available about the association between peripheral arterial disease (PAD) and SLE. We aimed to perform a meta-analysis of studies evaluating the association between SLE and PAD.
111. Effect of biologics on radiographic progression of peripheral joint in patients with psoriatic arthritis: meta-analysis.
作者: Dongze Wu.;Chen Li.;Shuo Zhang.;Priscilla Wong.;Yihan Cao.;James F Griffith.;Xinlu Zhang.;Jieruo Gu.;Lai-Shan Tam.
来源: Rheumatology (Oxford). 2020年59卷11期3172-3180页
To determine the efficacy of biologics in preventing radiographic progression in peripheral joints of PsA patients.
112. Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis.
作者: Ana Rita Cruz-Machado.;Santiago Rodrigues-Manica.;Joana Leite Silva.;Irina Alho.;Constança Coelho.;Joana Duarte.;Cláudia Florêncio.;Fernando M Pimentel-Santos.;José Tavares-Costa.;Elsa Vieira-Sousa.
来源: Rheumatology (Oxford). 2020年59卷11期3158-3171页
To assess the efficacy of biologic DMARDs (bDMARDs) in achieving Assessment of Spondyloarthritis International Society partial remission (ASAS-PR) and/or Ankylosing Spondylitis Disease Activity Score inactive disease (ASDAS-ID), as remission-like surrogates, in axial SpA (axSpA).
113. Pharmacological prevention of fractures in patients undergoing glucocorticoid therapies: a systematic review and network meta-analysis.
作者: Jiawen Deng.;Zachary Silver.;Emma Huang.;Elena Zheng.;Kyra Kavanagh.;Aaron Wen.;Wei Cheng.;Johanna Dobransky.;Stephanie Sanger.;George Grammatopoulos.
来源: Rheumatology (Oxford). 2021年60卷2期649-657页
To perform a network meta-analysis (NMA) on the efficacy of antiosteoporotic interventions in the prevention of vertebral and non-vertebral fractures in adult patients taking glucocorticoids (GCs).
114. A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever.
作者: Jasmin B Kuemmerle-Deschner.;Raju Gautam.;Aneesh T George.;Syed Raza.;Kathleen G Lomax.;Peter Hur.
来源: Rheumatology (Oxford). 2020年59卷10期2711-2724页
To identify and summarize the existing evidence on the efficacy, effectiveness and safety of biologic therapies used, either as indicated or off-label, in the treatment of FMF.
115. The impact of smoking on prevalence of psoriasis and psoriatic arthritis.
作者: Ummugulsum Gazel.;Gizem Ayan.;Dilek Solmaz.;Servet Akar.;Sibel Z Aydin.
来源: Rheumatology (Oxford). 2020年59卷10期2695-2710页
In this systematic literature review and meta-analysis, we aimed to investigate the impact of cigarette smoking on the prevalence and incidence of psoriasis and psoriatic arthritis (PsA).
116. The benefit-risk balance for biological agents in juvenile idiopathic arthritis: a meta-analysis of randomized clinical trials.
作者: Natalia Cabrera.;Gabriela Avila-Pedretti.;Alexandre Belot.;Jean-Paul Larbre.;Sabine Mainbourg.;Agnès Duquesne.;Perrine Janiaud.;Behrouz Kassai.;Michel Cucherat.;Jean-Christophe Lega.
来源: Rheumatology (Oxford). 2020年59卷9期2226-2236页
To assess the net benefit of biological agents (BA) used in JIA.
117. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
作者: Mark C Genovese.;Eduardo Mysler.;Tetsuya Tomita.;Kim A Papp.;Carlo Salvarani.;Sergio Schwartzman.;Gaia Gallo.;Himanshu Patel.;Jeffrey R Lisse.;Andris Kronbergs.;Soyi Liu Leage.;David H Adams.;Wen Xu.;Helena Marzo-Ortega.;Mark G Lebwohl.
来源: Rheumatology (Oxford). 2020年59卷12期3834-3844页
The aim of this integrated analysis is to evaluate the long-term safety and tolerability of ixekizumab in adults with psoriasis, PsA and axial SpA.
118. Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis.
作者: Jun K Khoo.;Hayley Barnes.;Seraphina Key.;Ian N Glaspole.;Andrew J Östör.
来源: Rheumatology (Oxford). 2020年59卷9期2217-2225页
Small molecule tyrosine kinase inhibitors [smTKI, comprising mostly of Janus kinase (JAK) and to a lesser extent, spleen tyrosine kinase (SyK) inhibitors] modulate the cytokine receptor-mediated intracellular signal cascade, and are an effective treatment for autoimmune diseases and malignancies. As smTKI are novel, long-term safety is uncertain. Due to increasing use, characterization of their true adverse event profile is critical.
119. Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis.
作者: Joanna Shim.;Linda E Dean.;Maira Karabayas.;Gareth T Jones.;Gary J Macfarlane.;Neil Basu.
来源: Rheumatology (Oxford). 2020年59卷11期3408-3414页
Effective management of axial spondyloarthritis (axSpA)-related fatigue is a major unmet clinical need. Anti-TNF therapy may reduce fatigue levels, although any effect has yet to be definitively quantified and predictors of any such improvements are unknown.
120. Predicting response to topical non-steroidal anti-inflammatory drugs in osteoarthritis: an individual patient data meta-analysis of randomized controlled trials.
作者: Monica S M Persson.;Joanne Stocks.;Gyula Varadi.;Mohammad Hashem Hashempur.;Marienke van Middelkoop.;Sita Bierma-Zeinstra.;David A Walsh.;Michael Doherty.;Weiya Zhang.
来源: Rheumatology (Oxford). 2020年59卷9期2207-2216页
To identify predictors of the specific (difference between treatment and placebo) and overall (change from baseline in treatment arm) treatment effects of topical NSAIDs in OA.
|